CAR2 Anti-CD38 A2 CAR-T Cells

Verified

Overview

CAR2 Anti-CD38 A2 CAR-T Cells has the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity. CAR2 Anti-CD38 A2 CAR-T Cells are being evaluated in multiple myeloma (MM) and has successfully demonstrated strong preclinical anti-tumor activity in animal models.

SparkCures ID 314
Developed By Sorrento Therapeutics, Inc.
Generic Name CAR2 Anti-CD38 A2 CAR-T Cells
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

Patient Friendly Brochure

Download a patient-friendly brochure to learn more about this clinical trial and the best way to connect with the Roger Williams Medical Center.

SparkCures Verified

SparkCures is working closely with Sorrento Therapeutics, Inc. to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners